The Food and Drug Administration (FDA) commissioner nominee, Dr. Heidi Overton, has agreed to set a timeline and clear parameters for a safety study on the abortion medication mifepristone. This development comes as a result of efforts by Sen. Josh Hawley, R-Mo., a member of the Senate Health, Education, Labor, and Pensions (HELP) Committee. Hawley has been actively pressing for accountability from federal health officials regarding the delayed assessment.
Senator Hawley stated, “These are significant pro-life wins that help ensure a thorough study and the possible reinstatement of important safeguards on the abortion drug that were removed by President Biden.” He added that future commissioner nominees must also commit to these promises to earn his support.
The Trump administration has promised to finalize the study by March 2027, with the FDA pledging to implement regulatory changes based on the findings by September 2027. These changes would impact both brand-name mifepristone and generic versions.
The senator’s office mentioned that the study would analyze data from Medicaid and commercially available sources, covering periods before and after the Biden administration’s changes to restrictions on the drug. These changes removed requirements for in-person doctor visits and dispensing of the medication.
The FDA has faced criticism and postponements in releasing its review, which was initially promised for 2025. Dr. Overton expressed her intent to complete the review using appropriate data and qualified experts, making the scientific results as public as possible.
In March, Senator Hawley called on fellow Republicans to support his bill banning mifepristone. He argued that the drug is almost always fatal to the unborn child and poses significant dangers to women. He emphasized that drug companies profit from its distribution, largely shielded from liability, and urged Congress to address these concerns.
